Striatal activation by optogenetics induces dyskinesias in the 6-hydroxydopamine rat model of Parkinson disease

Movement Disorders

Volumn 32, Issue 4, 2017, Pages 530-537

  F Hernández, Ledia ^a,b   Castela, Ivan ^a   Ruiz DeDiego, Irene ^b,c   Obeso, Jose A ^a,b   Moratalla, Rosario ^b,c  

^a HM Hospitales   (Spain)

^b INSTITUTO DE SALUD CARLOS III   (Spain)

^c INSTITUTO CAJAL   (Spain)

Author keywords

dyskinesias; l dopa; medium spiny neurons; optogenetics; Parkinson disease

Indexed keywords

CHANNELRHODOPSIN; DOPAMINE; LEVODOPA; OXIDOPAMINE; RHODOPSIN; TRANSCRIPTION FACTOR FOSB; UNCLASSIFIED DRUG; ADRENERGIC RECEPTOR STIMULATING AGENT; ANTIPARKINSON AGENT; CHANNELRHODOPSIN 2, RAT; DYNORPHIN; FOSB PROTEIN, RAT; PROTEIN C FOS; TYROSINE 3 MONOOXYGENASE;

ADENO ASSOCIATED VIRUS; ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DORSOLATERAL STRIATUM; DYSKINESIA; EFFERENT NERVE; HEMISPHERE; HISTOPATHOLOGY; IMMUNOHISTOCHEMISTRY; INVOLUNTARY MOVEMENT; LASER; MALE; MEDIAL FOREBRAIN BUNDLE; MEDIUM SPINY NEURON; NERVE CELL EXCITABILITY; NONHUMAN; OPTODYSKINESIA; OPTOGENETICS; PARKINSON DISEASE; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; VIRUS PARTICLE; ADVERSE EFFECTS; ANIMAL; BRAIN; CORPUS STRIATUM; DISEASE MODEL; DYSKINESIAS; GENETIC TRANSDUCTION; GENETICS; HEMISPHERIC DOMINANCE; METABOLISM; PATHOLOGY; SPRAGUE DAWLEY RAT;

ADRENERGIC AGENTS; ANIMALS; ANTIPARKINSON AGENTS; BRAIN; CORPUS STRIATUM; DISEASE MODELS, ANIMAL; DYNORPHINS; DYSKINESIAS; FUNCTIONAL LATERALITY; LEVODOPA; MALE; OPTOGENETICS; OXIDOPAMINE; PARKINSON DISEASE; PROTO-ONCOGENE PROTEINS C-FOS; RATS; RATS, SPRAGUE-DAWLEY; RHODOPSIN; TRANSDUCTION, GENETIC; TYROSINE 3-MONOOXYGENASE;

EID: 85014277392     PISSN: 08853185     EISSN: 15318257     Source Type: Journal    
DOI: 10.1002/mds.26947     Document Type: Article

References (31)

1. Aquino CC, Fox SH. Clinical spectrum of levodopa-induced complications. Mov Disord 2015;30:80-89.
2. Jenner P. Molecular mechanisms of L-DOPA-induced dyskinesia. Nat Rev Neurosci 2008;9:665-677.
3. Kravitz A V, Freeze BS, Parker PR, et al. Regulation of parkinsonian motor behaviors by optogenetic control of basal ganglia circuitry. Nature 2010;466:622-626.
4. Cui G, Jun SB, Jin X, et al. Concurrent activation of striatal direct and indirect pathways during action initiation. Nature 2013;494:238-242.
5. Tecuapetla F, Matias S, Dugue GP, et al. Balanced activity in basal ganglia projection pathways is critical for contraversive movements. Nat Commun 2014;5:4315.
6. Tecuapetla F, Jin X, Lima SQ, Costa RM. Complementary contributions of striatal projection pathways to action initiation and execution. Cell 2016;166:1-13.
7. Pavón N, Martín AB, Mendialdua A, Moratalla R. ERK phosphorylation and FosB expression are associated with L-DOPA-induced dyskinesia in hemiparkinsonian mice. Biol Psychiatry 2006;59:64-74.
8. Darmopil S, Martín AB, De Diego IR, et al. Genetic inactivation of dopamine D1 but not D2 receptors inhibits L-DOPA-induced dyskinesia and histone activation. Biol Psychiatry 2009;66:603-613.
9. Aubert I, Guigoni C, Häkansson K, et al. Increased D1 dopamine receptor signaling in levodopa-induced dyskinesia. Ann Neurol 2005;57:17-26.
10. Suárez LM, Solís O, Caramés JM, et al. L-DOPA treatment selectively restores spine density in dopamine receptor d2-expressing projection neurons in dyskinetic mice. Biol Psychiatry 2014;75:711-722.
11. Fieblinger T, Graves SM, Sebel LE, et al. Cell type-specific plasticity of striatal projection neurons in parkinsonism and L-DOPA-induced dyskinesia. Nat Commun 2014;5:5316.
12. Calabresi P, Pisani A, Rothwell J, et al. Hyperkinetic disorders and loss of synaptic downscaling. Nat Neurosci 2016;19:868-875.
13. Carta M, Bezard E. Contribution of pre-synaptic mechanisms to l-DOPA-induced dyskinesia. Neuroscience 2011;198:245-251.
14. Schirinzi T, Madeo G, Martella G, et al. Early synaptic dysfunction in Parkinson's disease: insights from animal models. Mov Disord 2016;31:802-813.
15. Breger LS, Dunnett SB, Lane EL. Comparison of rating scales used to evaluate l-DOPA-induced dyskinesia in the 6-OHDA lesioned rat. Neurobiol Dis 2013;50:142-150.
16. Solís, O., Garcia-Montes, J.R., González-Granillo, A., Xu, M., Moratalla, R., Dopamine D3 receptor modulates L-DOPA-induced dyskinesia by targeting D1 receptor-mediated striatal signaling. Cereb. Cortex, 2015, 27(1): 435-446.
17. Granado N, Ares-Santos S, Oliva I, et al. Dopamine D2-receptor knockout mice are protected against dopaminergic neurotoxicity induced by methamphetamine or MDMA. Neurobiol Dis 2011;42:391-403.
18. Ares-Santos S, Granado N, Espadas I, et al. Methamphetamine causes degeneration of dopamine cell bodies and terminals of the nigrostriatal pathway evidenced by silver staining. Neuropsychopharmacology 2014;39:1066-1080.
19. Schneider CA, Rasband WS, Eliceiri KW. NIH Image to ImageJ: 25 years of image analysis. Nat Methods 2012;9:671-675.
20. Ruiz-Dediego I, Mellstrom B, Vallejo M, et al. Activation of DREAM (Downstream Regulatory Element Antagonistic Modulator), a calcium-binding protein, reduces L-DOPA-induced dyskinesias in mice. Biol Psychiatry 2015;77:95-105.
21. Nadjar A, Gerfen CR, Bezard E. Priming for l-dopa-induced dyskinesia in Parkinson's disease: a feature inherent to the treatment or the disease? Prog Neurobiol 2009;87:1-9.
22. Bateup HS, Santini E, Shen W, et al. Distinct subclasses of medium spiny neurons differentially regulate striatal motor behaviors. Proc Natl Acad Sci U S A 2010;107:14845-14850.
23. Olanow CW, Gracies JM, Goetz CG, et al. Clinical pattern and risk factors for dyskinesias following fetal nigral transplantation in parkinson's disease: a double blind video-based analysis. Mov Disord 2009;24:336-343.
24. Hagell P, Piccini P, Björklund A, et al. Dyskinesias following neural transplantation in Parkinson's disease. Nat Neurosci 2002;5:627-628.
25. Freed CR, Greene PE, Breeze RE, et al. Transplantation of embryonic dopamine neurons for severe Parkinson's disease. N Engl J Med 2001;344:710-719.
26. Iderberg H, Rylander D, Bimpisidis Z, Cenci MA. Modulating mGluR5 and 5-HT1A/1B receptors to treat l-DOPA-induced dyskinesia: effects of combined treatment and possible mechanisms of action. Exp Neurol 2013;250:116-124.
27. Lindgren HS, Andersson DR, Lagerkvist S, et al. L-DOPA-induced dopamine efflux in the striatum and the substantia nigra in a rat model of Parkinson's disease: temporal and quantitative relationship to the expression of dyskinesia. J Neurochem 2010;112:1465-1476.
28. Carlsson T, Carta M, Muñoz A, et al. Impact of grafted serotonin and dopamine neurons on development of L-DOPA-induced dyskinesias in parkinsonian rats is determined by the extent of dopamine neuron degeneration. Brain 2009;132:319-335.
29. Bordia T, Perez XA, Heiss JE, et al. Optogenetic activation of striatal cholinergic interneurons regulates L-dopa-induced dyskinesias. Neurobiol Dis 2016; 91:47-58.
30. Ding Y, Won L, Britt JP, et al. Enhanced striatal cholinergic neuronal activity mediates L-DOPA-induced dyskinesia in parkinsonian mice. Proc Natl Acad Sci U S A. 2011;108:840-845.
31. Gardoni F, Di Luca M. Targeting glutamatergic synapses in Parkinson's disease. Curr Opin Pharmacol 2015;20:24-28.